S

Shanghai MicroPort EP Medtech Co Ltd
SSE:688351

Watchlist Manager
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Watchlist
Price: 19.98 CNY 1.16% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Shanghai MicroPort EP Medtech Co Ltd?
Write Note

Net Margin
Shanghai MicroPort EP Medtech Co Ltd

3.8%
Current
-0.1%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3.8%
=
Net Income
11.2m
/
Revenue
291.5m

Net Margin Across Competitors

Country CN
Market Cap 9.4B CNY
Net Margin
4%
Country US
Market Cap 199B USD
Net Margin
14%
Country US
Market Cap 191.3B USD
Net Margin
29%
Country US
Market Cap 141.3B USD
Net Margin
16%
Country US
Market Cap 134.2B USD
Net Margin
11%
Country IE
Market Cap 104.6B USD
Net Margin
13%
Country US
Market Cap 65.6B USD
Net Margin
9%
Country DE
Market Cap 58.1B EUR
Net Margin
8%
Country US
Market Cap 44.5B USD
Net Margin
74%
Country CN
Market Cap 311.1B CNY
Net Margin
33%
Country US
Market Cap 36.3B USD
Net Margin
9%
No Stocks Found

Shanghai MicroPort EP Medtech Co Ltd
Glance View

Market Cap
9.4B CNY
Industry
Health Care

Shanghai MicroPort EP Medtech Co. Ltd. has carved a distinct niche for itself within the rapidly evolving medical device industry, primarily focusing on electrophysiology. This innovative field deals with diagnosing and treating arrhythmias—irregular heartbeats that affect countless individuals globally. MicroPort EP's flagship products include advanced catheter-based systems and cardiac mapping technologies that physicians utilize to pinpoint and correct these heart rhythm disorders. Their solutions are intricately designed to improve the accuracy and effectiveness of ablation procedures, allowing for non-invasive interventions that can significantly enhance patient outcomes. By capitalizing on the increasing prevalence of cardiovascular ailments and the push towards less invasive medical treatments, the company has positioned itself as a pivotal player in the healthcare sector, gaining a competitive edge with its sophisticated R&D capabilities and product innovation. The company's revenue model revolves around the development, manufacturing, and sales of its proprietary electrophysiology devices. By investing heavily in research and development, MicroPort EP continually advances its product offerings, aiming to stay ahead of its competitors and meet the growing demands of healthcare professionals and patients alike. Sales are driven both domestically, within China's burgeoning healthcare market, and internationally, tapping into the global need for cutting-edge cardiac solutions. The integration of technology and healthcare expertise underscores their commitment to quality and innovation, ensuring a sustainable model as they advance in this niche sector. Ultimately, their financial performance reflects a strategic alignment with health trends and technological progress, allowing them to capture value in a market poised for significant growth.

Intrinsic Value
7.21 CNY
Overvaluation 64%
Intrinsic Value
Price
S

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3.8%
=
Net Income
11.2m
/
Revenue
291.5m
What is the Net Margin of Shanghai MicroPort EP Medtech Co Ltd?

Based on Shanghai MicroPort EP Medtech Co Ltd's most recent financial statements, the company has Net Margin of 3.8%.